Table 1.
Demographic and clinical characteristics of the patients with COVID-19.
| Patient Cohort | With Virus Persistence (Mean ± SD) |
With Rapid Virus Clearance (Mean ± SD) |
|---|---|---|
| Number | 7 (2 Male/5 Female) | 8 (3 Male/5 Female) |
| Age (Years) | 60.14 ± 3.58 | 38.25 ± 5.28 |
| ICU assistance | 3/7 | 1/8 |
| ECMO support | 2/7 | 1/8 |
| Mortality | 1/7 (14.3%) | 1/8 (12.5%) |
| Virus burden at presentation: | ||
| E gene, Ct value | 26.02 ± 3.59 | 25.75 ± 2.67 |
| RdRp1 gene, Ct value | 27.87 ± 5.68 | 25.88 ± 4.53 |
| RdRp2 gene, Ct value | 26.35 ± 5.27 | 25.61 ± 4.73 |
| N gene, Ct value | 28.52 ± 5.34 | 27.99 ± 4.04 |
| Virus clearance | ||
| Days, PSO | 24.14 ± 4.33 | 10.25 ± 0.56 |
| Anti-spike IgG antibody Response in sera: | ||
| Peak levels | 677.2 ± 217.8 | 76.70 ± 32.11 |
| Time for peak (Days, PSO) | 17.43 ± 2.61 | 11.13 ± 2.48 |
| Virus-neutralizing antibodies | ||
| Capacity/unit sera (Peak levels) | 168.00 ± 63.42 | 29.68 ± 14.82 |
| Time for peak (Days, PSO) | 30.43 ± 7.80 | 12.20 ± 5.17 |
| Efficacy/unit antibody (Peak levels) | 41.37 ± 11.49 | 35.70 ± 8.78 |
| Time for peak (Days, PSO) | 34.14 ± 7.15 | 12.50 ± 2.35 |